Viatris
88 articles about Viatris
-
Read the latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
-
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
4/15/2024
Viatris Inc. today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
A federal appeals court Monday backed Teva and Viatris’ challenge to a lower court ruling, finding that the companies can again make their case against Johnson & Johnson’s patent covering its schizophrenia drug Invega Sustenna.
-
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States
4/1/2024
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States.
-
With Monday’s FDA rejection of their long-acting glatiramer acetate formulation, Viatris and Mapi Pharma continue the biopharma industry’s recent losing streak in multiple sclerosis.
-
The FDA will kick off March with three target action dates, including one for an insomnia treatment and another for a multiple sclerosis therapy.
-
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
2/28/2024
Viatris Inc. announced its financial results for the fourth quarter and full year 2023.
-
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
2/28/2024
Viatris Inc. and Idorsia Ltd announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
-
Under the research and development agreement announced Wednesday, Viatris is securing global rights to Idorsia’s late-stage heart and lupus candidates.
-
Idorsia and Viatris enter into a significant global research and development collaboration
2/28/2024
Idorsia Ltd announced that it has entered into agreements for a significant global research and development collaboration with Viatris Inc.
-
5 FDA Decisions to Watch in Q1
1/2/2024
Iovance’s lifileucel for advanced melanoma and Madrigal’s resmetirom for nonalcoholic steatohepatitis are just a couple of the key decisions on the FDA's docket this quarter. -
Viatris Partners With Comfort Cases to Support Youth in U.S. Foster Care
11/21/2023
Viatris, a global healthcare company, announced that it has packed 1,000 backpacks in partnership with Comfort Cases, a nonprofit organization that provides comfort and personal care items for children entering the foster care system.
-
Viatris to Participate in the 2023 Jefferies London Healthcare Conference
11/14/2023
Viatris Inc., a global healthcare company, announced the company will participate in the Jefferies London Healthcare Conference in London, UK on Wednesday, November 15, 2023.
-
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
11/13/2023
Viatris Inc., a global healthcare company, and Theravance Biopharma, Inc. announced positive results from the YUPELRI® Phase III placebo-controlled clinical trial conducted in China assessing the efficacy and safety of YUPELRI, a once-daily nebulized long-acting muscarinic antagonist for the maintenance treatment of patients with COPD.
-
Rajiv Malik to Retire as President of Viatris Effective April 1, 2024
10/20/2023
Viatris Inc., a global healthcare company, announced that its President, Rajiv Malik, will be retiring as an executive of the Company effective April 1, 2024.
-
Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.
10/10/2023
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc.
-
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
10/1/2023
Viatris Inc. announced it has received an offer for the divestiture of substantially all of its Over-the-Counter business, and has entered into definitive agreements to divest its Women's Healthcare business, its Active Pharmaceutical Ingredients business in India and commercialization rights in certain non-core markets that were acquired as part of the Upjohn Transaction.
-
The companies on Wednesday secured the regulator’s approval for their eye drop Ryzvumi for the reversal of pharmacologically-induced mydriasis, as Viatris looks to add $1 billion in sales by 2028.
-
Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution)
9/27/2023
Viatris Inc. and Ocuphire Pharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI™.